Home   >  
Protease/Metabolic Enzyme
  • Microbiology/Virology
  >  
Integrase
  • HIV
  >   Dolutegravir sodium
Dolutegravir sodium Chemical Structure

Dolutegravir sodium

Data Sheet For research use only. Not for human use.
Cat. No. :BCP11890CAS No. :1051375-19-9Purity:98%
 Tel: 0086-13026320035   or   orders@biochempartner.com
Real-Time Inquiry ×

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • Chemical Properties&Biological Activity
CAS No. 1051375-19-9 Cat. No. BCP11890
Name Dolutegravir sodium
Synonyms Dolutegravir sodium salt;S/GSK1349572 sodium;GSK 1349572A;GSK-1349572A;GSK1349572A;
SMILES
Chemical Name
Formula C20H18F2N3NaO5 M. Wt 441.36
Purity 98% Storage Store at 4-8°C
Description Dolutegravir (DTG, GSK1349572) is metabolized primarily by uridine diphosphate glucuronyltransferase (UGT)1A1, with a minor role of cytochrome P450 (CYP)3A, and with renal elimination of unchanged drug being extremely low (< 1% of the dose). Fifty-three percent of the total oral dose is excreted unchanged in the feces but it is unknown if all or part of this is due to unabsorbed drug or some percentage of biliary excretion of the glucuronide conjugate which can be further degraded to form the parent compound in the gut lumen. The current Food and Drug Administration (FDA) draft guidance for renal impairment studies states that a pharmacokinetic (PK) study in patients with renal impairment should be conducted even for those drugs primarily metabolized or secreted in bile, because renal impairment can inhibit some pathways of hepatic and gut drug metabolism and transport.
  • Quality Control&Technical Support
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.

Recommend Products

More >

Tags:Dolutegravir sodium supplier,Dolutegravir sodium purchase,Dolutegravir sodium manufacturer,Dolutegravir sodium distributor,Dolutegravir sodium cost,Dolutegravir sodium buy,Dolutegravir sodium for sale

0086-13720134139